The US mRNA therapeutics market size was estimated at USD 11.07 billion in 2023 and is predicted to rake around USD 38.21 billion by 2033 with a CAGR of 13.21% from 2024 to 2033.
Key Points
- By type, the prophylactic vaccines segment held the largest share of the market in 2023.
- By application, the infectious disease segment led the market in 2023. The segment is observed to sustain the growth rate during the forecast period.
- By end-use, the hospital and clinics segment held the largest share of the market in 2023. The segment is expected to sustain its position throughout the forecast period.
The US mRNA therapeutics market has witnessed a remarkable surge in recent years, driven by advancements in biotechnology and the increasing focus on personalized medicine. mRNA, or messenger RNA, is a pivotal molecule in the field of biotechnology that plays a crucial role in the translation of genetic information into protein synthesis. This emerging therapeutic approach has garnered significant attention for its potential to treat a wide array of diseases, ranging from infectious diseases to various types of cancers.
The COVID-19 pandemic acted as a catalyst, accelerating the development and adoption of mRNA-based vaccines, which not only showcased the versatility of this technology but also demonstrated its rapid response capability in the face of evolving health threats. Beyond vaccines, the market is witnessing a burgeoning pipeline of mRNA therapeutics addressing diverse medical conditions, reflecting a promising future for this innovative approach.
Get a Sample: https://www.precedenceresearch.com/sample/3862
Growth Factors
Several factors contribute to the growth of the US mRNA therapeutics market. The robust investment in research and development, coupled with favorable regulatory environments, has facilitated the rapid progression of mRNA therapies from experimental concepts to tangible treatment options. The versatility of mRNA as a therapeutic platform, capable of addressing various diseases by encoding different proteins, has attracted significant investment from pharmaceutical companies and venture capitalists.
Moreover, the successful commercialization of COVID-19 mRNA vaccines has boosted confidence in the technology, encouraging further exploration for applications beyond infectious diseases. As the understanding of mRNA biology deepens, the potential for developing targeted and personalized therapies for conditions such as rare genetic disorders and certain types of cancers becomes increasingly feasible, driving sustained growth in the market.
US mRNA Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 13.21% |
| U.S. Market Size in 2023 | USD 11.07 Billion |
| U.S. Market Size by 2033 | USD 38.21 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, and By End User |
US mRNA Therapeutics Market Dynamics
Drivers:
Key drivers propelling the US mRNA therapeutics market include advancements in delivery technologies, increased understanding of mRNA pharmacology, and the expanding landscape of collaborations between biopharmaceutical companies and research institutions. Improved delivery systems have enhanced the stability and efficiency of mRNA molecules, overcoming previous challenges associated with their use in therapeutic applications.
Additionally, a deeper comprehension of mRNA pharmacology has led to the optimization of dosing regimens and reduction of potential side effects, further establishing the safety and efficacy profile of mRNA therapeutics. Collaborations between industry players and academic institutions have facilitated the pooling of expertise, resources, and infrastructure, fostering a collaborative environment that accelerates the development and commercialization of mRNA-based therapies.
Opportunities:
The US mRNA therapeutics market presents a multitude of opportunities, ranging from the exploration of novel therapeutic targets to the expansion of applications across different therapeutic areas. The adaptability of mRNA technology allows for the rapid development of vaccines and therapies in response to emerging infectious diseases or evolving strains of pathogens.
Furthermore, the personalized medicine approach enabled by mRNA therapeutics opens avenues for tailoring treatments based on an individual’s genetic makeup, presenting opportunities for precision medicine across a spectrum of diseases. The ongoing research into the potential of mRNA in cancer immunotherapy and regenerative medicine creates exciting prospects for groundbreaking treatments that could revolutionize the way various diseases are managed and treated.
Restraints:
Despite the promising outlook, the US mRNA therapeutics market faces certain challenges and restraints. High development costs, coupled with the complexities associated with large-scale production and distribution, pose financial and logistical hurdles for companies involved in mRNA therapeutic development.
Moreover, concerns about the long-term safety of mRNA therapies, potential off-target effects, and the need for stringent cold-chain storage for certain formulations present challenges that must be addressed to ensure widespread adoption. Additionally, regulatory uncertainties regarding the approval and reimbursement of mRNA therapies could impede their seamless integration into mainstream healthcare practices.
Read Also: Telecom Electronic Manufacturing Services Market Size, Report By 2033
Competitive Landscape:
The competitive landscape of the US mRNA therapeutics market is characterized by a dynamic interplay between established pharmaceutical companies and innovative biotech startups. Major players such as Moderna and Pfizer have demonstrated their prowess with the successful development and commercialization of COVID-19 mRNA vaccines, solidifying their positions as key contributors to the market.
Simultaneously, a surge of smaller biotech firms specializing in mRNA technologies has emerged, leveraging nimbleness and innovation to explore niche therapeutic areas. Collaborations and partnerships between industry giants and smaller players have become prevalent, aiming to harness collective expertise and resources for accelerated development and market penetration.
US mRNA Therapeutics Market Companies
- GSK plc.
- BioNTech SE
- CureVac N.V.
- Sangamo Therapeutics, Inc.
- Translate Bio, Inc.
- Moderna, Inc.
- Argos Therapeutics Inc.
- Arcturus Therapeutics
- AstraZeneca plc.
- Pfizer Inc.
- CRISPR Therapeutics AG
Recent Developments:
- In July 2023, MIT scientists are leading a three-year research study financed by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research that intends to build the first fully integrated, continuous mRNA production platform in history. The project is valued at $82 million. In addition to accelerating the development and production of mRNA technologies—which businesses are investing in at previously unheard-of levels in the hopes of creating novel vaccines and treatments for cancer, metabolic disorders, genetic diseases, and other conditions—the resulting pilot-scale system is meant to strengthen society’s capacity to respond to pandemics in the future.
Segments Covered in the Report
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
- Therapeutic Drugs
By Application
- Respiratory Diseases
- Oncology
- Rare Genetic Diseases
- Infectious Diseases
- Others
By End-use
- Research Organizations
- Hospitals & Clinics
- Others
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
